JCEM:HIV感染者过度肥胖和代谢功能障碍与RAAS活化期间利钠肽降低有关

2018-02-09 MedSci MedSci原创

众所周知利尿钠肽(NPs)对肾素 - 血管紧张素 - 醛固酮系统(RAAS)有负反馈作用,在维持心脏结构和维持代谢平衡方面起着关键作用。治疗良好的艾滋病毒感染者有脂肪重新分布的风险,并证明存在RAAS失调,这与代谢功能障碍有关。近日在JCEM上发表的一篇文章首次调查HIV感染者中与RAAS生理学和体成分指标有关的循环NPs。

众所周知利尿钠肽(NPs)对肾素 - 血管紧张素 - 醛固酮系统(RAAS)有负反馈作用,在维持心脏结构和维持代谢平衡方面起着关键作用。治疗良好的艾滋病毒感染者有脂肪重新分布的风险,并证明存在RAAS失调,这与代谢功能障碍有关。近日在JCEM上发表的一篇文章首次调查HIV感染者中与RAAS生理学和体成分指标有关的循环NPs。

研究人员在20例HIV感染者和10例非感染者中使用低钠控制饮食评估RAAS急性激活期间的心房利钠肽(ANP)、脑利钠肽(BNP)和氨基末端B型利钠肽(NT-proBNP)的水平。

研究结果显示与非HIV感染者相比,HIV感染者的BNP(60 [44,152]vs 196 [91,251],P = 0.04)显着降低而血清醛固酮水平升高。在HIV感染人群中, BNP水平与腰围(r = -0.46,P = 0.04)、BMI(r = -0.55,P = 0.01)、身体肥胖指数(r = -0.49,P = 0.03)、代谢指标[总胆固醇(r = -0.44,P = .05),HOMA-IR(r = -0.44,P = .05),MAP(r = -0.44,P = .05)]、血清醛固酮(r = -0.49,P = 0.03)呈显着副相关。这些关系并没有在非HIV组中得到证实。在根据HIV血清状态和BMI高于/低于25 kg / m2确定的四组比较中,BNP在各组之间显着降低,非HIV且BMI <25 kg / m2的组最高,BMI> 25 kg / m2的HIV最低(总P = 0.01)。

上述研究表明HIV感染者过度肥胖时,其相对减少的NP,特别是BNP,可能有助于减少醛固酮的抑制,并有可能引起醛固酮介导的代谢并发症。针对RAAS阻断和/或增加NP的新策略可能有助于减少HIV感染者中受到干扰的心脏代谢疾病。

原始出处:

Caitlin A Murphy.et al. Excessive Adiposity and Metabolic Dysfunction Relate to Reduced Natriuretic Peptide During RAAS Activation in HIV. J Clin Endocrinol Metab. 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

本文系梅斯医学(MedSci)原创编译整理,转载需授权!
本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063151, encodeId=ca2a2063151e1, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 17 15:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777769, encodeId=cdb71e77769e3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 26 08:03:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290222, encodeId=4de212902221f, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315132, encodeId=83751315132da, content=<a href='/topic/show?id=fd321505e00' target=_blank style='color:#2F92EE;'>#RAAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15057, encryptionId=fd321505e00, topicName=RAAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366475, encodeId=436d13664e555, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421147, encodeId=32db142114ebe, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
    2018-10-17 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063151, encodeId=ca2a2063151e1, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 17 15:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777769, encodeId=cdb71e77769e3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 26 08:03:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290222, encodeId=4de212902221f, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315132, encodeId=83751315132da, content=<a href='/topic/show?id=fd321505e00' target=_blank style='color:#2F92EE;'>#RAAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15057, encryptionId=fd321505e00, topicName=RAAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366475, encodeId=436d13664e555, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421147, encodeId=32db142114ebe, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
    2018-05-26 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063151, encodeId=ca2a2063151e1, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 17 15:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777769, encodeId=cdb71e77769e3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 26 08:03:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290222, encodeId=4de212902221f, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315132, encodeId=83751315132da, content=<a href='/topic/show?id=fd321505e00' target=_blank style='color:#2F92EE;'>#RAAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15057, encryptionId=fd321505e00, topicName=RAAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366475, encodeId=436d13664e555, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421147, encodeId=32db142114ebe, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063151, encodeId=ca2a2063151e1, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 17 15:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777769, encodeId=cdb71e77769e3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 26 08:03:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290222, encodeId=4de212902221f, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315132, encodeId=83751315132da, content=<a href='/topic/show?id=fd321505e00' target=_blank style='color:#2F92EE;'>#RAAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15057, encryptionId=fd321505e00, topicName=RAAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366475, encodeId=436d13664e555, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421147, encodeId=32db142114ebe, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
    2018-02-11 venlin
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063151, encodeId=ca2a2063151e1, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 17 15:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777769, encodeId=cdb71e77769e3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 26 08:03:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290222, encodeId=4de212902221f, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315132, encodeId=83751315132da, content=<a href='/topic/show?id=fd321505e00' target=_blank style='color:#2F92EE;'>#RAAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15057, encryptionId=fd321505e00, topicName=RAAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366475, encodeId=436d13664e555, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421147, encodeId=32db142114ebe, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2063151, encodeId=ca2a2063151e1, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Oct 17 15:03:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777769, encodeId=cdb71e77769e3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sat May 26 08:03:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290222, encodeId=4de212902221f, content=<a href='/topic/show?id=f774890827' target=_blank style='color:#2F92EE;'>#HIV感染者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8908, encryptionId=f774890827, topicName=HIV感染者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315132, encodeId=83751315132da, content=<a href='/topic/show?id=fd321505e00' target=_blank style='color:#2F92EE;'>#RAAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15057, encryptionId=fd321505e00, topicName=RAAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366475, encodeId=436d13664e555, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421147, encodeId=32db142114ebe, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sun Feb 11 10:03:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]

相关资讯

AIDS:服用五种或以上处方药会增加艾滋病风险

服用五种或五种以上处方药会增加感染艾滋病病毒的老年人和无艾滋病毒的成人的住院和死亡风险。这项由耶鲁大学牵头的研究结果突出了为多种疾病患者开具额外药物的潜在风险。

Sci Transl Med:HIV新疗法!

艾滋病是一种危害性极大的传染病,由HIV病毒引起。HIV是一种能攻击人体免疫系统的病毒。它把人体免疫系统中最重要的CD4+T淋巴细胞作为主要攻击目标,大量破坏该细胞,使人体丧失免疫功能,导致人体易于感染各种疾病,并可发生恶性肿瘤,病死率较高。目前常用的治疗是ART干预,但效果不佳,有研究发现,或许是肠道归巢蛋白(α-4β-7)搞的鬼。

抗艾新“武器”!我国内地HIV治疗单片复方制剂上市

近日,葛兰素史克(GSK)宣布,其控股合资公司ViiV Healthcare1的以新一代整合酶抑制剂多替拉韦为核心的单片复方制剂多替阿巴拉米片在中国内地上市,这也是我国内地HIV治疗领域的首个完整治疗方案的单片复方制剂,将使HIV治疗更为方便、高效。

J Clin Invest:全新研究找到HIV“隐藏蓄水池”的秘密,或能将HIV一网打尽!

最近一项旨在消除艾滋病病毒的“踢杀”研究揭示了寻找治疗方法的潜在障碍。乔治华盛顿大学的研究人员最近的一项研究发现,潜伏的HIV蓄水池对CD8 T细胞有抵抗力,CD8 T细胞是一种白细胞,其主要功能是杀死受感染的细胞。

PLOS Medicine: Fc修饰的HIV-1人单克隆抗体-VRC01LS的安全性和药代动力学研究

背景:VRC01是人类体内一种针对HIV-1包膜糖蛋白(Env)的CD4结合位点的单克隆抗体(bnMAb),目前本研究验证了IIb期成人HIV-1预防效果。 而VRC01LS是VRC01的修改版本,其方法是通过增加对新生儿Fc受体的结合亲和力来延长血清半衰期。

PNAS:HIV新突破,血液检测成为过去,唾液检测准确率100%!

在一份最新的报告中,研究人员表示,一项基于唾液的实验性艾滋病检测显示出了希望。这项新的测试能够像血液测试一样可靠地检测出唾液中HIV抗体的早期证据。